We are live on ! Find out more
SCV

Sands Capital Ventures Portfolio holdings

AUM $614M
1-Year Est. Return 19.92%
This Fund
S&P 500
This Quarter Est. Return
-24.06%
1 Year Est. Return
+19.92%
3 Year Est. Return
+166.76%
5 Year Est. Return
+157.76%
10 Year Est. Return
–
AUM
$479M
AUM Growth
-$196M
Cap. Flow
+$26.4M
Cap. Flow %
5.52%
Top 10 Hldgs %
93.53%
Holding
18
New
2
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
CINC
CinCor Pharma, Inc. Common Stock
CINC
+$19.5M
2
OLK
Olink Holding AB (publ) American Depositary Shares
OLK
+$6.94M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 32.9%
2 Technology 28.56%
3 Financials 14.74%
4 Consumer Discretionary 14.73%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PATH icon
1
UiPath
PATH
$8.3B
$82.3M 17.19%
3,811,779
– –
NU icon
2
Nu Holdings
NU
$73.6B
$70.5M 14.74%
9,136,835
– –
DASH icon
3
DoorDash
DASH
$94B
$70.5M 14.73%
601,454
– –
DICE
4
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
$60.2M 12.59%
3,148,970
– –
SNOW icon
5
Snowflake
SNOW
$114B
$49.2M 10.27%
214,621
– –
KRTX
6
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$34M 7.1%
267,895
– –
CINC
7
DELISTED
CinCor Pharma, Inc. Common Stock
CINC
$16.7M 3.48%
+950,000
New +$19.5M
ABOS icon
8
Acumen Pharmaceuticals
ABOS
$193M
$13.4M 2.79%
3,417,075
– –
OLK
9
DELISTED
Olink Holding AB (publ) American Depositary Shares
OLK
$7.51M 1.57%
+425,514
New +$6.94M
MASS icon
10
908 Devices
MASS
$414M
$6.21M 1.3%
326,427
– –
IOT icon
11
Samsara
IOT
$23.2B
$5.22M 1.09%
326,000
– –
TSHA icon
12
Taysha Gene Therapies
TSHA
$1.94B
$4.73M 0.99%
724,873
– –
TARS icon
13
Tarsus Pharmaceuticals
TARS
$3.04B
$4.37M 0.91%
260,000
– –
RGEN icon
14
Repligen
RGEN
$9.42B
$4.24M 0.89%
22,544
– –
CADL icon
15
Candel Therapeutics
CADL
$897M
$4.13M 0.86%
811,737
– –
SPRB
16
Spruce Biosciences
SPRB
$151M
$1.58M 0.33%
10,493
– –
ABSI icon
17
Absci
ABSI
$1.58B
$487K 0.1%
57,804
– –

Similar funds

T2I
Turim 21 Investimentos Rio De Janeiro, Brazil $613M AUM 14.25% 1-Year Est. Return
VAG
VisionPoint Advisory Group Dallas, Texas $613M AUM 30.37% 1-Year Est. Return
MKA
M. Kulyk & Associates Decatur, Georgia $613M AUM 22.75% 1-Year Est. Return
CSIA
Conrad Siegel Investment Advisors Harrisburg, Pennsylvania $615M AUM 21.19% 1-Year Est. Return
ATFA
All Terrain Financial Advisors Coon Rapids, Minnesota $615M AUM 30.42% 1-Year Est. Return
AA
Aire Advisors Beverly Hills, California $615M AUM 25.07% 1-Year Est. Return
FWM
Fonville Wealth Management Richmond, Virginia $612M AUM 18.82% 1-Year Est. Return
FSA
Financial Security Advisor Virginia Beach, Virginia $615M AUM 26.08% 1-Year Est. Return

Sands Capital Ventures's Q1 2022 Portfolio in Review

As of Q1 2022, Sands Capital Ventures held 18 positions worth $479M, down 29% from $675M the previous quarter. Its ten largest holdings account for 94% of the portfolio.

Sands Capital Ventures deployed $26.4M of net new capital in Q1 2022, opening 2 new positions. Its largest new stake was CinCor Pharma, Inc. Common Stock: 950,000 shares worth $16.7M.

By sector, the portfolio is most concentrated in Healthcare at 33% of assets, up from 26% a quarter earlier, followed by Technology and Financials.

  • Sands Capital Ventures's largest Q1 2022 buy was CinCor Pharma, Inc. Common Stock: 950,000 shares worth $16.7M.
  • Sands Capital Ventures's ten largest holdings make up 94% of its $479M portfolio in Q1 2022.
  • Sands Capital Ventures opened 2 new positions and closed 0 in Q1 2022.
  • Sands Capital Ventures's portfolio value fell 29% quarter-over-quarter to $479M.

Based on Sands Capital Ventures's 13F filing for Q1 2022, filed 13 May 2022.